DOCSLIB.ORG

Epileptic and Depressed Magdalena Romanowicz, MD, and John Michael Bostwick, MD

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Epileptic and Depressed Magdalena Romanowicz, MD, and John Michael Bostwick, MD Cases That Test Your Skills Epileptic and depressed Magdalena Romanowicz, MD, and John Michael Bostwick, MD Ms. R, age 33, seeks treatment for worsening depression after her How would you epilepsy diagnosis 1 year ago. She has a history of bulimia and handle this case? Visit CurrentPsychiatry.com ongoing anxiety and chronic pain. How would you manage her? to input your answers and see how your colleagues responded CASE New-onset seizures What is the most likely explanation for Ms. R’s Ms. R, age 33, is referred by her neurologist worsening depressive symptoms? for treatment of depressive symptoms that a) major depressive disorder (MDD) second- have intensified after she was diagnosed with ary to a general medical condition epilepsy 1 year ago. She has a history of buli- b) MDD, recurrent mia and ongoing anxiety and depression. She c) chronic pain disorder also has long-standing neuropathic pain in d) somatoform disorder her left lateral shin and ankle that started after e) substance-induced mood disorder her foot was amputated in a lawn mower ac- cident at age 5. Ms. R says she didn’t take pain The authors’ observations medication until age 24, when her pain spe- Tramadol, a centrally acting synthetic an- cialist prescribed tramadol, 300 to 400 mg/d, algesic, consists of 2 enantiomers that act which she continues to take. as weak agonists at µ-opioid receptors Ms. R’s first seizure occurred 1 year ago. while also inhibiting serotonin and norepi- Despite trials of several antiepileptics, her nephrine reuptake.1 Euphoria associated seizures persist; she is taking lamotrigine, 200 with µ receptor activation often is consid- mg/d, when she presents for treatment. She ered a “high.” Most abused opioids are has no history of brain injuries or strokes to prototypical µ agonists. When opioids are explain her epilepsy. An MRI and 3 electroen- injected or inhaled, drug levels in the brain cephalograms show no signs of focal, poten- rise rapidly, causing a “rush”—a brief, in- tially epileptogenic lesions. tense, pleasurable sensation—followed by Ms. R reports worsening depressive a longer-lasting high. Tolerance and physi- symptoms—particularly impaired attention cal dependence occur when opioids are and concentration—over several months that used chronically. interfere with her housekeeping and ability to Despite tramadol’s µ-opioid activity, finish simple tasks at work. She says she drinks the FDA approved it as an unscheduled alcohol occasionally, but denies substance analgesic in 1994 based on several human abuse. We initiate venlafaxine, titrated to studies.2 Experience with tramadol has 300 mg/d, because Ms. R has a history of confirmed it has low abuse potential, yet intolerable side effects with fluoxetine (gastrointestinal distress) and citalopram Dr. Romanowicz is a Child and Adolescent Psychiatry Fellow, Stanford University, Stanford, CA. Dr. Bostwick is Professor of Current Psychiatry (weight gain). Psychiatry, Mayo Clinic, Rochester, MN. Vol. 11, No. 5 45 Cases That Test Your Skills Table 1 Tramadol and seizures DSM-IV-TR criteria for pain At clinically appropriate doses, tramadol disorder slightly suppresses seizure severity,6 but higher doses can induce seizures.7-12 This A) Pain in ≥1 anatomical site is the predominant paradox is explained by tramadol’s effect focus of the clinical presentation and is of sufficient severity to warrant clinical attention on γ-aminobutyric acid (GABA) receptors. Although at clinical doses tramadol does B) The pain causes clinically significant distress or impairment in social, occupational, or not affect GABA, which could precipitate other important areas of functioning seizures, at higher doses it has been shown C) Psychological factors are judged to have to have an inhibitory effect on GABA re- an important role in the onset, severity, ceptors.13,14 No prospective studies have exacerbation, or maintenance of the pain assessed how often tramadol-induced sei- Clinical Point D) The symptom or deficit is not intentionally zures occur. Case reports12,15 suggest that produced or feigned (as in factitious disorder seizures are more likely with acute tramad- or malingering) At clinically ol intoxication, in patients with a history of appropriate doses, E) The pain is not better accounted for by a alcohol abuse, or with pharmacologic regi- mood, anxiety, or psychotic disorder and tramadol slightly does not meet criteria for dyspareunia mens that include other medications that may cause seizures. Tramadol-induced suppresses seizure Source: Reference 17 severity, but higher seizures are generalized tonic-clonic in na- ture, and typically occur within 24 hours of doses can induce the last dose.16 seizures human laboratory data—and some epi- demiologic data—show that repeated use can lead to physical dependence. Although HISTORY Worsening seizures tramadol is considered a relatively weak Two months after she presents for psychiat- opioid, human studies suggest that it pos- ric evaluation, Ms. R experiences 6 general- sesses µ-agonist activity. The Drug Abuse ized convulsions lasting from 15 minutes to 1 Warning Network reported >15,000 emer- hour with no identifiable precipitant. Because gency department (ED) visits for nonmedi- oxcarbazepine and lamotrigine have failed to cal tramadol use in 2009, which was more suppress her seizures, her neurologist adds than the number of ED visits for codeine phenytoin, 200 mg/d, and increases lamotri- products (7,958) or propoxyphene prod- gine from 200 to 300 mg/d. Her depression ucts (9,526), but much fewer than visits continues to worsen. She reports severe insom- for hydrocodone (86,258) or oxycodone nia, anhedonia, restlessness, and hopelessness, (148,449) products.3 so we add sertraline, 50 mg/d, to venlafaxine. The recommended tramadol dose is Ms. R says the seizures are terrifying and she 50 to 100 mg every 4 to 6 hours (maxi- cannot work. She moves in with her parents be- mum 400 mg/d). Adverse effects range cause she is unable to care for herself. from dysphoria, constipation, and nausea During a psychiatric appointment, Ms. R to agitation, seizures, respiratory depres- confesses that for 2 years her pain has been Discuss this article at sion, and coma.4 Tramadol withdrawal so unbearable that she has been buying extra www.facebook.com/ is similar to opioid withdrawal, and is tramadol from Internet retailers and taking CurrentPsychiatry characterized by anxiety, restlessness, in- 600 to 800 mg/d in addition to the prescribed somnia, yawning, rhinorrhea, lacrimation, 400 mg/d. diaphoresis, tremor, muscle spasms, vom- iting, diarrhea, and tachycardia. Rarely, How would you manage Ms. R? psychomotor agitation and confusion a) ask for her permission to discuss her Current Psychiatry 46 May 2012 may occur.5 tramadol abuse with her neurologist Cases That Test Your Skills Table 2 Tramadol: Major drug-drug interactions Drug Symptoms Selegiline Nausea, vomiting, cardiovascular collapse, respiratory depression, seizures, or serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status changes); use of the transdermal formulation with tramadol is contraindicated Carbamazepine Decreased tramadol efficacy and increased seizure risk Venlafaxine Increased risk of serotonin syndrome Linezolid Increased risk of serotonin syndrome Fluoxetine Increased risk of seizures and serotonin syndrome; increased concentrations of tramadol and decreased concentrations of tramadol active metabolite, O-desmethyltramadol (M1) Olanzapine Increased risk of serotonin syndrome Clinical Point Mirtazapine Increased risk of serotonin syndrome Haloperidol Increased risk of seizures Seizures have been Escitalopram Increased risk of seizures and serotonin syndrome observed with Clomipramine Increased risk of seizures tramadol doses as low Risperidone Increased risk of seizures as 100 mg/d Ketamine Increased risk of respiratory depression and excessive CNS depression Imipramine Increased risk of seizures Duloxetine Increased risk of serotonin syndrome Nortriptyline Increased risk of seizures Clozapine Increased risk of seizures Sertraline Increased risk of seizures and serotonin syndrome Paroxetine Increased risk of seizures and serotonin syndrome; decrease in the analgesic effect of tramadol Amitriptyline Increased risk of seizures; increased concentrations of tramadol and decreased concentrations of tramadol active metabolite, M1 Desipramine Increased risk of seizures Doxepin Increased risk of seizures Citalopram Increased risk of seizures and serotonin syndrome Fluvoxamine Increased risk of seizures and serotonin syndrome Source: Reference 19 b) try to manage her condition on your own antiepileptics was unsuccessful. Her sei- c) report her to her employer and ask zures persisted as long as her tramadol ad- preventive health services to follow up on diction continued. her treatment Spiller et al18 reported the lowest daily d) none of the above tramadol dose associated with seizures is 500 mg/d, although Talaie et al16 observed The authors’ observations seizures at doses as low as 100 mg/d. Ms. R had a history of chronic pain (Table Additionally, seizure risk may increase 1)17 and developed seizures after escalating through tramadol’s interactions with her tramadol use. After her first epilepsy several medications, including tricyclic attack, she did not tell her physicians she antidepressants, selective serotonin reup- was taking additional tramadol nor did take inhibitors, phenothiazines, fluoroqui- Current Psychiatry she stop taking it. Treatment with several nolone antibiotics,
Load more

Recommended publications
  • Canadian Stroke Best Practice Recommendations
    CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS MOOD, COGNITION AND FATIGUE FOLLOWING STROKE Table 1C: Summary Table for Selected Pharmacotherapy for Post-Stroke Depression Update 2019 Lanctôt KL, Swartz RH (Writing Group Chairs) on Behalf of the Canadian Stroke Best Practice Recommendations Mood, Cognition and Fatigue following Stroke Writing Group and the Canadian Stroke Best Practice and Quality Advisory Committee, in collaboration with the Canadian Stroke Consortium © 2019 Heart & Stroke Heart and Stroke Foundation Mood, Cognition and Fatigue following Stroke Canadian Stroke Best Practice Recommendations Table 1C Table 1C: Summary Table for Selected Pharmacotherapy for Post-Stroke Depression This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on selected classes of medications available for use in Canada and more commonly recommended for post-stroke depression. This table should be used as a reference guide by health care professionals when selecting an appropriate agent for individual patients. Patient compliance, patient preference and/or past experience, side effects, and drug interactions should all be taken into consideration during decision-making, in addition to other information provided in this table and available elsewhere regarding these medications. Selective Serotonin Reuptake Inhibitors (SSRI) Serotonin–norepinephrine reuptake Other inhibitors (SNRI) Medication *citalopram – Celexa *duloxetine – Cymbalta methylphenidate – Ritalin (amphetamine)
    [Show full text]
  • The Pharma-Fever That Almost Got Away
    EMERGENCY MEDICINE RESIDENCY CPC The pharma-fever that almost got away XIAO CHI ZHANG, MD, MS; MATTHEW SIKET, MD; WILLIAM BINDER, MD 29 31 EN From the Case Records of the Alpert Medical School of DR. SARAH GAINES: A fever greater than 41.0°C is quite Brown University Residency in Emergency Medicine elevated and unusual. Is this dangerous? What was your differential? DR. XIAO CHI ZHANG: A 68-year-old man was brought into DR. MATTHEW SIKET: Humans generally tolerate tempera- the Emergency Department by his family with chills and tures below 41° C (105.8° F). In contrast to hyperthermia, in altered mental status. Two days prior to his ED presenta- which an imbalance between heat generation versus dissipa- tion, the patient had an episode in which he “spaced-out” tion occurs without up-regulation of the hypothalamic set and was unable to comprehend or acknowledge his wife. She point, fever as a host defense against infection rarely reaches reported that he did not have any signs of seizure activity dangerous levels in neurologically competent individuals. and did not have any focal weakness. The episode lasted Very high temperatures can be related to urosepsis, intraab- approximately 30 minutes and he returned to his baseline. dominal sepsis, C. difficile colitis, meningitis, and central Today he had another episode, but this time associated with venous catheter infections. Hyperpyrexia, defined as tem- chills and rigors. His past medical history was significant perature > 41.5°C (106.7°F) is an uncommon result of infec- for chronic back pain due to bony metastasis from Stage IV tion and usually implies central fever, neurologic malignant non-small cell lung adenocarcinoma, requiring palliative syndrome, malignant hyperthermia, adrenal insufficiency, gamma knife radiation, as well as a daily oral chemotherapy or a drug related cause.1 Our patient was hyperpyrexic, sug- agent, erlotinib, an oral tyrosine kinase inhibitor.
    [Show full text]
  • PRESCRIBED DRUGS and NEUROLOGICAL COMPLICATIONS K a Grosset, D G Grosset Iii2
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.2004.045757 on 16 August 2004. Downloaded from PRESCRIBED DRUGS AND NEUROLOGICAL COMPLICATIONS K A Grosset, D G Grosset iii2 J Neurol Neurosurg Psychiatry 2004;75(Suppl III):iii2–iii8. doi: 10.1136/jnnp.2004.045757 treatment history is a fundamental part of the healthcare consultation. Current drugs (prescribed, over the counter, herbal remedies, drugs of misuse) and how they are taken A(frequency, timing, missed and extra doses), drugs tried previously and reason for discontinuation, treatment response, adverse effects, allergies, and intolerances should be taken into account. Recent immunisations may also be of importance. This article examines the particular relevance of medication in patients presenting with neurological symptoms. Drugs and their interactions may contribute in part or fully to the neurological syndrome, and treatment response may assist diagnostically or in future management plans. Knowledge of medicine taking behaviour may clarify clinical presentations such as analgesic overuse causing chronic daily headache, or severe dyskinesia resulting from obsessive use of dopamine replacement treatment. In most cases, iatrogenic symptoms are best managed by withdrawal of the offending drug. Indirect mechanisms whereby drugs could cause neurological problems are beyond the scope of the current article—for example, drugs which raise blood pressure or which worsen glycaemic control and consequently increase the risk of cerebrovascular disease, or immunosupressants
    [Show full text]
  • Catatonia, NMS, and Serotonin Syndrome
    Catatonia, NMS, and Serotonin Syndrome Christopher M. Celano, MD, FACLP Associate Director, Cardiac Psychiatry Research Program, Massachusetts General Hospital Assistant Professor of Psychiatry, Harvard Medical School October 22, 2020 www.mghcme.org Disclosure: Christopher Celano, MD Sunovion Company Pharmaceuticals Employment Management Independent Contractor Consulting Speaking & Teaching I Board, Panel or Committee Membership D – Relationship is considered directly relevant to the presentation I – Relationship is NOT considered directly relevant to the presentation www.mghcme.org Catatonia: How common is it? • 7.8-9.0% prevalence rate – Highest rates in non-psychiatric (i.e., medical) settings and in patients undergoing ECT. • 1.6-5.5% of all patients seen on psychiatry consultation service – Prevalence higher for older patients • Up to 46% of cases may have etiology that is not primarily psychiatric Grover 2015, Carroll 1994, Jaimes-Albornoz 2013, Fricchione 2008 www.mghcme.org When are you called? • Staff reports the patient is “Playing POSSUM” • Perseveration (speech or behavior) • Oppositionality to all requests • Speech that trails off or is whispereD • Slowed response to questions or commands • Undernourished (reports of decreased PO intake) • Motionless but awake www.mghcme.org Diagnosing Catatonia: DSM-5 DSM-5 requires 3 or more of the following: • Catalepsy • Posturing • Waxy flexibility • Mannerisms • Stupor • Stereotypies • Agitation • Grimacing • Mutism • Echolalia • Negativism • Echopraxia American Psychiatric Association 2013 www.mghcme.org Bush-Francis Rating Scale • Excitement • VerBigeration • Immobility/stupor • Rigidity • ComBativeness • Negativism • Autonomic Abnormality • Waxy flexiBility • Impulsivity • Withdrawal • Mutism • Automatic OBedience • Staring • Mitgehen • Posturing/catalepsy • Gegenhalten • Grimacing • AmBitendency • Echopraxia/echolalia • Grasp Reflex • Stereotypy • Perseveration • Mannerisms Bush 1996 www.mghcme.org Challenges with Diagnosis • Clarifying specific symptoms can be difficult – Rigidity vs.
    [Show full text]
  • Triptan Therapy for Acute Migraine
    Triptan Therapy for Acute Migraine Headache John Farr Rothrock, MD University of Alabama at Birmingham, Birmingham, AL Deborah I. Friedman, MD, MPH University of Texas Southwestern, Dallas, TX The “triptans” are 5HT-1B/1D receptor agonists that were developed to treat acute migraine and acute cluster headache. Sumatriptan, the original triptan preparation, has been in general use since 1993, so there has been considerable experience with triptans over time. There are currently seven oral triptans on the market in the United States: sumatriptan (Imitrex™), naratriptan (Amerge™), zolmitriptan (Zomig™), rizatriptan (Maxalt™), almotriptan (Axert™), frovatriptan (Frova™), and eletriptan (Relpax™); brand names may differ by country. There is also a combination preparation of oral sumatriptan/naproxen (Treximet™). Two triptans (sumatriptan, zolmitriptan) are marketed as nasal sprays, and sumatriptan is available for subcutaneous injection, including a needle-free subcutaneous delivery system (Sumavel™). Sumatriptan suppositories are marketed in Europe but not in North America. Zolmitriptan and rizatriptan are sold in an oral disintegrating tablet or “melt” formulation as well as in tablet form; while the “melt” formulations may be more convenient (no liquid is required to propel them into the stomach), they are absorbed similarly to regular tablets and there is no evidence to suggest that they work faster than the tablet formulations. Some patients with migraine-associated nausea prefer the disintegrating tablets while others cannot tolerate their taste. Although all of the triptans initially were investigated for the treatment of migraine headache of moderate to severe intensity and were superior to placebo in those pivotal trials, they appear to be more consistently effective when used to treat migraine earlier in the attack, when the headache is still mild to moderate.
    [Show full text]
  • Neuroleptic Malignant Syndrome Vs Serotonin Syndrome: Can They Be Distinguished Without an Underlying Etiology?
    Neuroleptic Malignant Syndrome vs Serotonin Syndrome: Can They Be Distinguished Without an Underlying Etiology? Roy R. Reeves, DO, PhD; Mark E. Ladner, MD; and Percy Smith, PA The potentially serious complications for patients with neuroleptic malignant syndrome and serotonin syndrome cannot be underplayed by mental health clinicians, patients, and their families. The authors discuss clinical similarities and diagnostic and treatment approaches to the 2 syndromes. euroleptic malignant syn- of symptoms or whether the patient ployment. He had stopped taking his drome (NMS) and sero- was taking different medications that medication (risperidone 3-mg daily) tonin syndrome (SS) are rare could affect both the serotonin and 3 months earlier, because he was Nbut potentially fatal condi- dopamine systems. experiencing adverse effects (AEs) tions associated with the treatment In clinical practice many patients and shortly thereafter hearing voices. of psychotropic medications. Neu- are treated concurrently with both The clinic psychiatrist started him on roleptic malignant syndrome is be- dopamine receptor antagonists and olanzapine 10-mg daily and sertra- lieved to be caused by a reduction in agents that increase serotonin activity. line 50-mg daily. At a follow-up visit dopaminergic activity secondary to Thus, the distinction of NMS and SS a week later, Mr. A showed an im- drug-induced dopaminergic block- may be problematic if these patients provement of his mood and reported age, whereas SS results from an ex- develop symptoms that could be at- that his hallucinations had decreased cess of central nervous system (CNS) tributed to either disorder. This article significantly. serotonin activity, usually because will discuss the clinical similarities of Several days later, Mr.
    [Show full text]
  • JAMA Neurology Pages 525-636
    In This Issue May 2018 Volume 75, Number 5 JAMA Neurology Pages 525-636 Research Opinion Amyloid and Tau Accumulation in Young Adults With ADAD 548 Viewpoint 531 Preventing Sudden Unexpected Although the medial temporal lobe is typically the first area of neurofibrillary tangle depo- Death in Epilepsy sition in aging populations, it is not clear if this is the case for younger individuals who are O Devinsky and Coauthors predisposed to autosomal dominant Alzheimer disease (ADAD). In a cross-sectional study, Quiroz and coauthors used positron emission tomography imaging to measure amyloid and Clinical Review & Education tau deposition in 24 participants (mean [SD] age, 38.0 [7.4] years) from a large Colombian Review kindred with ADAD. The authors report that amyloid accumulates in the cortex of unim- paired presenilin 1 E280A mutation carriers 10 to 15 years before symptom onset, whereas tau deposits emerge in the medial temporal lobe approximately 6 years before and then spread into the cortex as carriers move closer to clinical onset. These findings suggest that amyloid prompts the spread of tau pathology beyond the medial temporal lobe and that the presence of tau is closely associated with memory decline. Editorial perspective is pro- vided by McDade and Bateman. Editorial 536 Risk of Serotonin Syndrome With Triptans and Antidepressants 566 In 2006, the US Food and Drug Administration issued a warning regarding the potential risk of serotonin syndrome with coprescription of triptan antimigraine drugs and selective sero- 620 Review of the Neurological toninreuptakeinhibitororselectivenorepinephrinereuptakeinhibitorantidepressantsbased Implications of von Hippel–Lindau Disease D Dornbos III and Coauthors on a small number of case reports.
    [Show full text]
  • Catatonia, Serotonin Syndrome and Parkinsonism
    MJP Online Early 01-01-17 CASE REPORT A Diagnostic Dilemma: Catatonia, Serotonin Syndrome and Parkinsonism Mohd Miharbei MF1,2, Ahmad Zafri AB1, Suhaila MZ1 1Jabatan Psikiatri dan Kesihatan Mental, Hospital Tengku Ampuan Afzan, 25100 Kuantan, Pahang, Malaysia 2Department of Psychological Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia Abstract Catatonia may concomitantly occur with other psychiatric diagnoses such as Major Depressive Disorder, however problem in diagnosis may arise due to the overlapping features with other problems such as serotonin syndromes, neuroleptic malignant syndromes and Parkinsonism. Despite the diagnostic dilemma and lack of diagnostic tools, the clinical correlation between the carbon monoxide poisoning and the late-onset development of the Parkinsonian features is the highlight of this report. Keywords: Catatonia, Parkinsonism, Carbon Monoxide Poisoning Introduction symptoms such as stuporous nature of the patient, rigidity, tremor and bradykinesia. Catatonic syndromes are a diagnostic conundrum and always offer a therapeutic Despite the similarity, the option and challenge as well. Catatonia is an associated response towards treatment are quite feature in major psychiatric diagnoses, as different. While electroconvulsive therapy is well as a prominent overlapping features in a known treatment option in catatonic state, neuroleptic malignant syndrome, akinetic it may not be the case for the state of parkinsonism and representing motor serotonergic syndrome and Parkinsonism. features of serotonergic syndromes [1,3]. The list of the possible cause of similar Case report presentations are vast. Among others, carbon monoxide poisoning is known to Mr LHC, a 58 years old Chinese male, with cause delayed onset Parkinsonism [2]. background history of methamphetamine abuse, presented to the hospital following Among the said differentials, there are few unconsciousness episode at home.
    [Show full text]
  • Serotonin Syndrome in Stroke Patients
    J Rehabil Med 2015; 47: 282–285 CASE REPORT Serotonin SYNDROME IN STROKE patients Sung Ho Jang, MD1*, Yong Min Kwon, MD1* and Min Cheol Chang, MD2 From the 1Department of Physical Medicine and Rehabilitation, College of Medicine, Yeungnam University and 2Department of Physical Medicine and Rehabilitation, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. *These authors contributed equally to this study. Objective: Serotonin syndrome is a potentially life-threaten- Dopaminergic agents are known to be effective in improve- ing condition that can be caused by administration of agents ment of cognitive, language, motor, and executive function that increase serotonergic activity in the brain. We report in stroke patients (3). Therefore, dopaminergic drugs are here on 2 stroke patients who presented with serotonin syn- often prescribed for stroke patients during rehabilitation; drome following administration of dopaminergic agents. however, administration of dopaminergic drugs is associated Case report: Two stroke patients were administered ropin- with the risk of inducing SS (1, 4, 5). Although SS has been irole (patient 1) and carbidopa/levodopa (patient 2) during reported in other brain pathologies, including depressive rehabilitation. Both patients exhibited the clinical features of disorder and Parkinson’s disease, little is known about SS in serotonin syndrome, coinciding with an increase in dosage of stroke patients (5). each drug. Based on the clinical features included in revised We report here on 2 stroke patients who presented with SS Radomski’s criteria, they presented with 3 major symptoms after administration of dopaminergic agents. with 3 and 2 minor symptoms, respectively. The drugs that were thought to trigger serotonin syndrome were discontin- ued and the patients underwent conservative treatment.
    [Show full text]
  • Diagnosis of Serotonin Syndrome in the Intensive Care Population: a Case Report
    Netherlands Journal of Critical Care Accepted December 2013 CASE REPORT Diagnosis of serotonin syndrome in the intensive care population: a case report X. Zuidema1, I. Wilting2, M. Kromkamp3, J. Kesecioglu1 1Department of Intensive Care Medicine, Division of Anesthesiology, Intensive Care and Emergency Medicine Department of Intensive Care Medicine, University Medical Center Utrecht, the Netherlands 2Department of Clinical Pharmacy, Division Laboratory and Pharmacy, University Medical Center Utrecht, the Netherlands 3Department of Psychiatry, University Medical Center Utrecht, the Netherlands Correspondence X. Zuidema – e-mail: [email protected] Keywords – Serotonin syndrome, ICU, diagnosis Abstract by rapid treatment, however, is crucial, since a significant ICU admission due to serotonin syndrome (SS) is well proportion of SS cases (17%) lead to a worse outcome, with a described in the literature. However, development of SS during mortality rate of up to 0.2%.3 SS is mostly seen as a result of ICU admission has not been reported to date. We present a inadvertent interactions between serotonin-active drugs and/ patient in whom SS was suspected during ICU admission. or intentional self-poisoning.4,5 We describe a patient who was SS may be induced by either increased serotonergic activity suspected of SS during ICU admission, whilst continuing a or by lowering the cerebral serotonin sensitivity threshold. medication regime that included citalopram and amitriptyline. SS is not easily recognized, especially in ICU populations because it can easily be confused with clinical deterioration Case report or other drug-related toxidromes. SS is a potentially fatal A fifty-five year old somnolent male was admitted to the clinical syndrome, which requires rapid diagnosis and timely Department of Internal Medicine of a large academic teaching treatment.
    [Show full text]
  • Movement Disorders Emergencies Part 1 Hypokinetic Disorders
    NEUROLOGICAL REVIEW SECTION EDITOR: DAVID E. PLEASURE, MD Movement Disorders Emergencies Part 1 Hypokinetic Disorders Bradley J. Robottom, MD; William J. Weiner, MD; Stewart A. Factor, DO ovement disorders usually do not require emergent intervention; nevertheless, there are acute/subacute clinical settings in which the neurologist is consulted. It is in these circumstances that the neurologist must be prepared to accurately diagnose and properly treat the patient. We have reviewed the literature regarding move- Mment disorder emergencies and divided them into hypokinetic (part 1) and hyperkinetic (part 2) presentations. In part 1, drug-induced syndromes including neuroleptic malignant syndrome, par- kinsonism hyperpyrexia syndrome, and serotonin syndrome will be discussed. Emergency com- plications related to the management of Parkinson disease, including falling, motor fluctuations, and psychiatric issues, will also be reviewed. Arch Neurol. 2011;68(5):567-572 Movement disorders often have an insidi- DRUG-INDUCED MOVEMENT ous onset and slow progression and are not DISORDER EMERGENCIES often associated with emergency situa- tions. However, neurologists may be called Neuroleptic Malignant Syndrome on to diagnose and treat evolving move- ment disorders or acute complications of Neuroleptic malignant syndrome, first de- existing diseases in the emergency depart- scribed in 1960,2 is an iatrogenic disorder re- ment or intensive care unit. Such situa- sulting from exposure to drugs that block tions meet the working definition of an dopamine
    [Show full text]
  • Serotonin Syndrome in Asymptomatic Huntington's Disease
    Serotonin syndrome I Case notes Serotonin syndrome in asymptomatic Huntington’s disease Verity Haffenden BSc, MBBS, Anish Patel MBChB, MRCPsych, MedEd(Cert) Serotonin syndrome is a rare Figure 1. Hunter’s Criteria (adapted from Boyer and Shannon, 2005)6 and serious condition most often resulting from iatrogenic insult; the prescriber’s pen is Has a serotonergic agent been administered in the past five weeks? sometimes the most poisonous. Here, Dr Haffenden and Dr No Yes Patel discuss a complex case of serotonin syndrome in a patient with genetically proven, but not Not serotonin Are any of the following symptoms yet symptomatic, Huntington’s syndrome present? disease and chronic renal Tremor and hyperreflexia impairment. A screening Spontaneous clonus process is proposed to recognise the multitude of No Muscle rigidity, temperature >38°C, and Yes precipitating factors, which either ocular clonus or inducible clonus aligned in this case, and could Ocular clonus and either agitation or either alter our prescribing or diaphoresis expedite recognition. Inducible clonus and either agitation or diaphoresis untington’s disease (HD), a Hprogressive neurodegenerative Not serotonin Serotonin disease, is clinically diagnosed with syndrome syndrome a triad of signs/symptoms: chorea; psychiatric illness, and dementia. Research has shown neurotransmit- surgery was performed using a Past medical history of note ter deficits in mice models of Hun- cadaveric specimen but his postoper- included a genetic, but not yet tington’s1 both before and after ative period was complicated by anti- symptomatic, diagnosis of HD and symptomatic disease presence2 – body-mediated rejection and past psychiatric history included namely a reduction in serotonin.
    [Show full text]